Sam M. Rowe
Investigator, GSK
Sam M. Rowe is listed as Investigator, GSK. B2DB records 2 sessions at 1 conference in 2026, most recently Drug Discovery Chemistry Europe 2026 (November 2026). Speaks mainly at Hospitals and Health Care events.
Compiled from published conference agendas; not yet confirmed by Sam. Is this you? Claim this profile.
- Sector: Hospitals and Health Care
About
Sam is a Principal Scientist is the Chemical Biology Department at GSK. Prior to this, he completed a PhD in peptide chemistry at the University of Cambridge. Since joining GSK in 2021, Sam has worked extensively on the identification and optimisation of covalents hits and leads for drug discovery, with a particular focus on embedding Direct-to-Biology workflows.
Sessions at 1 conference
Drug Discovery Chemistry Europe 2026 11 November 2026 – 12 November 2026
- Direct-to-Biology (D2B) Applications for Degrader and Small Molecule Lead Generation Moderator · 10 November 2026
- Direct-to-Biology for WRN-Targeted Covalent Hit Identification and Optimisation Speaker · 10 November 2026
Spoke alongside
People who have shared a session with Sam at events on B2DB.
- Ryan A. Hollibaugh Associate Director · Jnana Therapeutics 1 shared session
Others from GSK
- Shobie Ramakrishnan Chief Digital and Technology Officer 2 sessions
- Anthony Rowe VP Onyx Research 1 session
- David Egan Assistant General Counsel, Global Digital and Privacy 1 session
- Ian Wall Head Molecular Design 1 session
- Jeffrey T. Hamilton Head, Payer Partnership & Policy - Global Pricing and Market Access 1 session
- Juergen Loskutov Scientific Leader, Bio Bank 1 session
- Libby Hamson Global Pricing and Market Access Director 1 session
- Luke Bellamy Director MSAT Systems & Informatics - Global Manufacturing Science & Technology 1 session
- Tim Ashlin Team Leader and Principal Investigator 1 session
- Yasmin Zobedey NHS Strategy, Portfolio and Partnerships Senior Manager 1 session